Uniphar (LON:UPR) Hits New 1-Year High – Should You Buy?

Uniphar plc (LON:UPR) shares hit a new 52-week high during trading on Friday . The stock traded as high as GBX 348 ($4.72) and last traded at GBX 348 ($4.72), with a volume of 8648 shares traded. The stock had previously closed at GBX 339 ($4.59).

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on UPR shares. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a GBX 375 ($5.08) target price on shares of Uniphar in a report on Wednesday, July 30th. Shore Capital reissued a “buy” rating on shares of Uniphar in a research note on Thursday, May 29th.

Uniphar Price Performance

The firm has a market cap of £1.07 billion, a P/E ratio of 23.93 and a beta of 0.75. The company has a quick ratio of 0.60, a current ratio of 0.90 and a debt-to-equity ratio of 119.48. The business’s 50 day moving average is GBX 326.96 and its two-hundred day moving average is GBX 269.20.

Uniphar Company Profile

Headquartered in Dublin, Ireland Uniphar plc is a diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology
manufacturers across three divisions – Commercial & Clinical, Product Access and Supply Chain & Retail. With a workforce of more than 2,000, the Group is active in Ireland, the UK and the Benelux.